The USPTO has issued a Notice of Allowance for Biomerica’s (NASDAQ:BMRA) first U.S. patent pertaining to the Company’s InFoods family of products that allow for new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases.
Specifically, this allowed application contains numerous claims that broadly cover a product that helps identify patient specific foods, that when removed, may alleviate or improve an individual’s IBS symptoms.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.